NasdaqGS - Nasdaq Real Time Price USD

Agios Pharmaceuticals, Inc. (AGIO)

Compare
42.69 +3.72 (+9.56%)
At close: December 16 at 4:00:01 PM EST
43.00 +0.31 (+0.73%)
After hours: December 16 at 6:41:31 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
32,871.00
26,823.00
14,240.00
--
--
Cost of Revenue
3,491.00
2,881.00
1,704.00
--
2,805.00
Gross Profit
29,380.00
23,942.00
12,536.00
--
200,391.00
Operating Expense
436,357.00
415,429.00
401,583.00
378,418.00
335,916.00
Operating Income
-406,977.00
-391,487.00
-389,047.00
-378,418.00
-335,916.00
Net Non Operating Interest Income Expense
38,692.00
33,344.00
12,793.00
836.00
6,611.00
Other Income Expense
1,095,713.00
6,055.00
144,453.00
21,072.00
--
Pretax Income
727,428.00
-352,088.00
-231,801.00
-356,510.00
-329,305.00
Net Income Common Stockholders
674,308.00
-352,088.00
-231,801.00
1,604,715.00
-327,370.00
Diluted NI Available to Com Stockholders
674,308.00
-352,088.00
-231,801.00
1,604,715.00
-327,370.00
Basic EPS
-6.50
-6.33
-4.23
26.55
-4.74
Diluted EPS
-6.50
-6.33
-4.23
26.55
-4.74
Basic Average Shares
56,230.09
55,651.49
54,789.44
60,447.35
68,997.88
Diluted Average Shares
56,230.09
55,651.49
54,789.44
60,447.35
68,997.88
Total Operating Income as Reported
-406,977.00
-391,487.00
-389,047.00
-378,418.00
-335,916.00
Total Expenses
439,848.00
418,310.00
403,287.00
378,418.00
335,916.00
Net Income from Continuing & Discontinued Operation
674,308.00
-352,088.00
-231,801.00
1,604,715.00
-327,370.00
Normalized Income
-186,109.44
-352,088.00
-369,505.00
-363,149.00
-329,305.00
Interest Income
38,692.00
33,344.00
12,793.00
836.00
6,611.00
Interest Expense
--
--
--
--
17,832.00
Net Interest Income
38,692.00
33,344.00
12,793.00
836.00
6,611.00
EBIT
-406,977.00
-391,487.00
-389,047.00
-378,418.00
-335,916.00
EBITDA
-401,288.00
-384,864.00
-380,483.00
-369,178.00
-326,126.00
Reconciled Cost of Revenue
3,491.00
2,881.00
1,704.00
--
2,805.00
Reconciled Depreciation
5,689.00
6,623.00
8,564.00
9,240.00
9,790.00
Net Income from Continuing Operation Net Minority Interest
674,308.00
-352,088.00
-231,801.00
-356,510.00
-329,305.00
Total Unusual Items Excluding Goodwill
1,089,136.00
--
137,704.00
6,639.00
--
Total Unusual Items
1,089,136.00
--
137,704.00
6,639.00
--
Normalized EBITDA
-1,490,424.00
-384,864.00
-518,187.00
-375,817.00
-326,126.00
Tax Rate for Calcs
0.00
--
--
--
--
Tax Effect of Unusual Items
228,718.56
--
--
--
--
12/31/2020 - 7/24/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NAMS NewAmsterdam Pharma Company N.V.
24.71
+0.08%
 
WVE Wave Life Sciences Ltd.
13.45
+0.07%
 
KROS Keros Therapeutics, Inc.
19.42
+3.13%
 
FOLD Amicus Therapeutics, Inc.
9.90
+5.77%
 
NUVL Nuvalent, Inc.
87.42
+0.64%
 
ANAB AnaptysBio, Inc.
16.65
+6.80%
 
QTTB Q32 Bio Inc.
3.5000
-5.41%
 
BGNE BeiGene, Ltd.
176.33
-1.68%
 
BCYC Bicycle Therapeutics plc
15.12
+9.49%
 
QURE uniQure N.V.
17.40
+12.99%